Annex

QUESTIONNAIRE FOR THE TESTING OF THE GUIDANCE ON RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

GENERAL INFORMATION ABOUT THE TESTING									
		☐ Party. Please specify: Slovakia							
Q1. These results are being submitted on behalf of a:	Other Government. Please specify: <country's name=""></country's>								
	Organization: Please specify: <organization's name=""></organization's>								
Q2. When was the testing of the Guidance conducted?	Please enter date: 4.10 22.11.2011								
Q3. Type of event where the testing of the Guidance was conducted?	\boxtimes	Group event (e.g., workshop, training course, meeting). Please provide the title of the event and name of organizer: Meeting of Committee for Biological Safety and its Expert Panel, Ministry of Environment of Slovak Republic							
		Type of meeting:							
		⊠ Online							
		Individual exercise. Please provide your name, occupation and affiliation: <type here=""></type>							
		Other: Plea	ase specify: <	Type here>					
Q4. Which sections of the Guidance were tested?	Part I: The Roadmap for Risk assessment of LMOs								
	Part II: Specific types of LMOs or Traits:								
	☐ Risk assessment of LMOs with stacked genes or traits								
	Risk assessment of LM crops with tolerance to abiotic stress								
		☐ Risk assessment of LM mosquitoes							
OVERALL EVALUATION									
			Very poor	Poor	Neutral	Good	Very good		
Please indicate the level of agreement you a	ıttribute	e to each of th	he questions	in the left col	<u>lumn.</u>				
Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?									
Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in a scientifically sound and case-by-case manner?					\boxtimes				
Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs introduced into various receiving					\boxtimes				

Q15. Does the flowchart provide a useful graphic

representation of the risk assessment process as

described in the Roadmap?

PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS Please answer each of the questions in the left column with "yes" or "no" and add comments if needed. Does the Roadmap provide useful guidance X Yes for conducting risk assessments of LMOs in Comments: <Type here> □ No accordance with the Protocol? X Yes Is the Roadmap useful to risk assessors who Comments: <Type here> have limited experience with LMO risk assessment? ☐ No X Yes Q10. Is the Roadmap organized in a logic and Comments: <Type here> structured manner? ☐ No Q11. Is the Roadmap user-friendly taking into X Yes account that risk assessment is a complex scientific Comments: <Type here> ☐ No and multidisciplinary activity? X Yes Q12. Is the Roadmap applicable to all types of Comments: <Type here> LMOs (e.g. plants, animals, microorganisms)? ☐ No Q13. Is the Roadmap applicable to all types of X Yes introductions into the environment (e.g. small- and Comments: <Type here> large-scale releases, placing on the ☐ No market/commercialisation)? ☐ Yes Q14. Is there any other issue or concept that you Comments: <Type here> would like to see included in the Roadmap? ⊠ No

X Yes

☐ No

Comments: <Type here>

PART II: SPECIFIC TYPES OF LIVING MODIFIED ORGANISMS OR TRAITS

Risk assessment of living modified organisms with stacked genes or traits

		Ŭ				
Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.						
Q16. Does this section provide useful guidance when conducting risk assessments of LMOs with stacked genes or traits in accordance with the Protocol?	⊠ Yes □ No	Comments: <type here=""></type>				
Q17. Is this section of the Guidance useful to risk assessors who have limited experience with risk assessments of LMOs with stacked genes of traits?	⊠ Yes □ No	Comments: <type here=""></type>				
Q18. Is this section of the Guidance organized in a logic and structured manner?	⊠ Yes □ No	Comments: <type here=""></type>				
Q19. Is this section of the Guidance user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	⊠ Yes □ No	Comments: <type here=""></type>				
Q20. Is there any other issue or concept that you would like to see included in this section of the Guidance?	☐ Yes	Comments: <type here=""></type>				
Risk assessment of living modified crops with tolerance to abiotic stress						
Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.						
Q21. Does this section provide useful guidance when conducting risk assessments of LM crops with tolerance to abiotic stress(es) in accordance with the Protocol?	⊠ Yes □ No	Comments: <type here=""></type>				
Q22. Is this section of the Guidance useful to risk assessors who have limited experience with risk assessments of LM crops with tolerance to abiotic stress(es)?	⊠ Yes □ No	Comments: <type here=""></type>				
Q23. Is this section of the Guidance organized in a logic and structured manner?	⊠ Yes □ No	Comments: <type here=""></type>				
Q24. Is this section of the Guidance user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	⊠ Yes □ No	Comments: <type here=""></type>				
Q25. Is there any other issue or concept that you would like to see included in this section of the Guidance?	☐ Yes	Comments: <type here=""></type>				

Risk assessment of living modified mosquitoes						
Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.						
Q26. Does this section provide useful guidance when conducting risk assessments of LM mosquitoes in accordance with the Protocol?	☐ Yes ☐ No	Comments: <type here=""></type>				
Q27. Is this section of the Guidance useful to risk assessors who have limited experience with risk assessments of LM mosquitoes?	☐ Yes ☐ No	Comments: <type here=""></type>				
Q28. Is this section of the Guidance organized in a logic and structured manner?	☐ Yes ☐ No	Comments: <type here=""></type>				
Q29. Is this section of the Guidance user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	☐ Yes ☐ No	Comments: <type here=""></type>				
Q30. Is there any other issue or concept that you would like to see included in this section of the Guidance?	☐ Yes ☐ No	Comments: <type here=""></type>				
ADDITIONAL COMMENTS						
Please add any additional comment you may have regarding the "Guidance on Risk Assessment of Living Modified Organisms" below.						
Q31. <please comments="" here="" type="" your=""></please>						
